PL3662910T3 - Farmakofor do indukowania trail - Google Patents

Farmakofor do indukowania trail

Info

Publication number
PL3662910T3
PL3662910T3 PL19218049.5T PL19218049T PL3662910T3 PL 3662910 T3 PL3662910 T3 PL 3662910T3 PL 19218049 T PL19218049 T PL 19218049T PL 3662910 T3 PL3662910 T3 PL 3662910T3
Authority
PL
Poland
Prior art keywords
pharmacophore
trail induction
trail
induction
Prior art date
Application number
PL19218049.5T
Other languages
English (en)
Polish (pl)
Inventor
Kim D. Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of PL3662910T3 publication Critical patent/PL3662910T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19218049.5T 2014-03-31 2015-03-30 Farmakofor do indukowania trail PL3662910T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
PL3662910T3 true PL3662910T3 (pl) 2025-08-11

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15772254T PL3125898T3 (pl) 2014-03-31 2015-03-30 Farmakofor do indukcji trail
PL19218049.5T PL3662910T3 (pl) 2014-03-31 2015-03-30 Farmakofor do indukowania trail

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15772254T PL3125898T3 (pl) 2014-03-31 2015-03-30 Farmakofor do indukcji trail

Country Status (20)

Country Link
US (5) US10239877B2 (OSRAM)
EP (3) EP3125898B1 (OSRAM)
JP (4) JP6756435B2 (OSRAM)
KR (2) KR102473930B1 (OSRAM)
CN (2) CN111499636B (OSRAM)
AU (4) AU2015241069B2 (OSRAM)
CA (2) CA2944452C (OSRAM)
CY (1) CY1123093T1 (OSRAM)
DK (2) DK3125898T3 (OSRAM)
ES (2) ES2999685T3 (OSRAM)
FI (1) FI3662910T3 (OSRAM)
HR (2) HRP20241680T1 (OSRAM)
HU (2) HUE069651T2 (OSRAM)
LT (2) LT3125898T (OSRAM)
PL (2) PL3125898T3 (OSRAM)
PT (2) PT3662910T (OSRAM)
RS (2) RS60163B1 (OSRAM)
SI (2) SI3662910T1 (OSRAM)
SM (2) SMT202000219T1 (OSRAM)
WO (1) WO2015153468A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014244117B2 (en) 2013-03-13 2018-12-20 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
TR201906711T4 (tr) * 2013-11-15 2019-05-21 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hekzahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, bunun tuzları ve kullanım metotları.
JP6756435B2 (ja) * 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Trail誘導のためのファーマコフォア
JP6802172B2 (ja) * 2015-01-30 2020-12-16 オンコシューティクス インコーポレイテッドOncoceutics,Inc. 7−ベンジル−4−(2−メチルベンジル)−2,4,6,7,8,9−ヘキサヒドロイミダゾ[1,2−a]ピリド[3,4−e]ピリミジン−5(1h)−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
KR20250065717A (ko) * 2016-01-29 2025-05-13 온코슈틱스 인코포레이티드 이미프리돈에 의한 g 단백질-커플링된 수용체 (gpcr) 조절
AU2017310526B2 (en) 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
WO2020176654A1 (en) 2019-02-27 2020-09-03 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
KR20230106583A (ko) 2020-08-06 2023-07-13 에오토보스 로란드 투도만예게템 신규한 이미프리돈 유도체의 합성 및 이들의 항암 활성에 대한 평가
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
EP1517904A4 (en) * 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
US8071636B2 (en) * 2008-06-09 2011-12-06 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療
US8691832B2 (en) * 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
EA028904B1 (ru) * 2011-03-15 2018-01-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Изоксазолидиновые производные
EP2694678A2 (en) * 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
SMT202400421T1 (it) 2011-04-29 2024-11-15 Penn State Res Found Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
AU2014244117B2 (en) * 2013-03-13 2018-12-20 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
JP6756435B2 (ja) * 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Trail誘導のためのファーマコフォア

Also Published As

Publication number Publication date
CN106456643A (zh) 2017-02-22
US10633385B2 (en) 2020-04-28
EP3125898A1 (en) 2017-02-08
LT3662910T (lt) 2024-12-27
AU2024204977A1 (en) 2024-08-08
EP3125898B1 (en) 2019-12-25
HRP20241680T1 (hr) 2025-02-28
AU2015241069A1 (en) 2016-10-20
JP2021119157A (ja) 2021-08-12
CN111499636B (zh) 2023-01-13
SI3125898T1 (sl) 2020-07-31
WO2015153468A1 (en) 2015-10-08
US10239877B2 (en) 2019-03-26
JP6873201B2 (ja) 2021-05-19
CN106456643B (zh) 2020-04-17
RS66254B1 (sr) 2024-12-31
EP4470617A2 (en) 2024-12-04
US11891392B2 (en) 2024-02-06
RS60163B1 (sr) 2020-05-29
CA2944452A1 (en) 2015-10-08
US20220002300A1 (en) 2022-01-06
ES2999685T3 (en) 2025-02-26
SMT202000219T1 (it) 2020-05-08
EP4470617A3 (en) 2025-02-26
SMT202400497T1 (it) 2025-01-14
US20200283440A1 (en) 2020-09-10
AU2015241069B2 (en) 2020-10-15
US20190284188A1 (en) 2019-09-19
CY1123093T1 (el) 2021-10-29
KR102473930B1 (ko) 2022-12-05
JP2023022184A (ja) 2023-02-14
DK3662910T3 (en) 2024-11-04
EP3662910A1 (en) 2020-06-10
HUE069651T2 (hu) 2025-03-28
AU2020286314A1 (en) 2021-01-21
PL3125898T3 (pl) 2020-11-16
PT3662910T (pt) 2024-11-27
CA3158795A1 (en) 2015-10-08
US20240190877A1 (en) 2024-06-13
KR20220163533A (ko) 2022-12-09
US20170107221A1 (en) 2017-04-20
CN111499636A (zh) 2020-08-07
SI3662910T1 (sl) 2025-05-30
JP2017511321A (ja) 2017-04-20
JP6756435B2 (ja) 2020-09-16
PT3125898T (pt) 2020-04-01
EP3125898A4 (en) 2017-08-16
HRP20200478T1 (hr) 2020-07-24
AU2022283729A1 (en) 2023-02-02
DK3125898T3 (da) 2020-03-30
EP3662910B1 (en) 2024-09-18
KR102611067B1 (ko) 2023-12-06
JP7186256B2 (ja) 2022-12-08
HUE049013T2 (hu) 2020-08-28
KR20160138513A (ko) 2016-12-05
CA2944452C (en) 2022-07-19
JP7688245B2 (ja) 2025-06-04
FI3662910T3 (fi) 2024-10-31
LT3125898T (lt) 2020-04-10
ES2779979T3 (es) 2020-08-21
JP2020002170A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
GB2531928B (en) Image-stitching for dimensioning
GB201817189D0 (en) Image-stitching for dimensioning
DK3662910T3 (en) Pharmacophore for trail induction
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201411418D0 (en) Compounds
GB201415573D0 (en) Compounds
GB201410430D0 (en) Compounds
GB201416186D0 (en) Compounds
GB201402431D0 (en) Compounds
GB201406591D0 (en) Compounds
GB201406956D0 (en) Compounds
GB201404987D0 (en) Compounds
GB2524311B (en) Centraliser
GB201412660D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
GB201407695D0 (en) Compounds
GB201403438D0 (en) Polymorphs
GB2525001B (en) Centraliser
GB201405361D0 (en) Compounds
IL233408A0 (en) New Skin - Perineal
GB201416116D0 (en) Compounds
GB201415570D0 (en) Compounds
GB201415571D0 (en) Compounds
AP2014007674A0 (en) Chengie-advanced claypot de-fluoridation technology
GB201413527D0 (en) Compounds